论文部分内容阅读
近年来,随着医学分子生物学的发展,分子靶向治疗作为恶性肿瘤治疗的新手段,正日益受着临床工作者们的重视。其中表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinases inhibitor,EGFR-TKI)在非小细胞肺癌中的作用也逐渐受到肯定。然而在临床中,有些患者对EGFR-TKI的治疗并不敏感或对该类药物产生耐药,故对EGFR-TKI耐药机制的探索成为国内外研究的热点,本文现就EGFR-TKI耐药机制的研究进展进行综述。
In recent years, with the development of medical molecular biology, molecular targeted therapy as a new approach to the treatment of malignant tumors is increasingly being valued by clinicians. The role of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer has gradually been recognized. However, in clinical practice, some patients are not sensitive to EGFR-TKI treatment or have developed resistance to this class of drugs. Therefore, the exploration of the mechanism of EGFR-TKI resistance has become a hot topic at home and abroad. This article is about EGFR-TKI resistance. The research progress of the mechanism is reviewed.